97628-92-7

Usage

Uses

Used in Organic Synthesis:
1-(Benzyloxycarbonyl)azetidine-3-carboxylic acid is used as a building block in organic synthesis for the preparation of various other compounds. Its unique structure allows for the creation of a wide range of chemical entities, contributing to the diversity of organic chemistry.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 1-(Benzyloxycarbonyl)azetidine-3-carboxylic acid is used as a component in the preparation of pharmaceutical compounds. Its potential pharmacological properties make it a promising candidate for the development of new drugs.
Used as an Antibacterial Agent:
1-(Benzyloxycarbonyl)azetidine-3-carboxylic acid has been studied for its antibacterial properties, making it a candidate for use as an antibacterial agent in the medical and pharmaceutical fields. Its ability to combat bacterial infections could lead to the development of new treatments and therapies.
Used in Drug Development Research:
As a valuable tool for researchers, 1-(Benzyloxycarbonyl)azetidine-3-carboxylic acid is used in drug development research to explore its potential applications and properties. Its unique structure and functional groups provide a foundation for investigating new chemical reactions and syntheses, contributing to the advancement of pharmaceutical science.

InChI:InChI=1S/C12H13NO4/c14-11(15)10-6-13(7-10)12(16)17-8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,15)

Upstream product

• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 36476-78-5 3-azetidinecarboxylic acid 
• 501-53-1 benzyl chloroformate 
• 757239-60-4 O₁-benzyl-O₃-methylazetidine-1,3-dicarboxylate 

Downstream Products

• 1015005-67-0 C₁₇H₂₃N₃O₅ 
• 1228230-77-0 3-(2-iodo-phenylcarbamoyl)-azetidine-1-carboxylic acid benzyl ester 
• 1228230-73-6 azetidine-1,3-dicarboxylic acid 1-benzyl ester 3-(2-oxo-propyl)ester 
• 1236144-51-6 O₁-benzyl-O₃-tert-butylazetidine-1,3-dicarboxylate 
• 1238877-83-2 benzyl 3-[(4-cyclobutylpiperazin-1-yl)carbonyl]azetidine-1-carboxylate 
• 1238876-21-5 benzyl 3-[(4-cyclobutyl-1,4-diazepan-1-yl)carbonyl]azetidine-1-carboxylate 
• 618446-42-7 benzyl 3-(hydroxymethyl)azetidine-1-carboxylate 

Relevant academic research and scientific papers

COMPOUNDS, COMPOSITIONS AND METHODS

The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.

NOVEL COMPOUNDS

The invention relates to compounds of Formula (I) and their use in therapy, for example in the treatment of mycobacterial infections or in the treatment of diseases caused by mycobacterium, such as tuberculosis

Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based Series

Sphingosine 1-phosphate (S1P) is the endogenous ligand for the sphingosine 1-phosphate receptors (S1P1-5) and evokes a variety of cellular responses through their stimulation. The interaction of S1P with the S1P receptors plays a fundamental physiological role in a number of processes including vascular development and stabilization, lymphocyte migration, and proliferation. Agonism of S1P1, in particular, has been shown to play a significant role in lymphocyte trafficking from the thymus and secondary lymphoid organs, resulting in immunosuppression. This article will detail the discovery and SAR of a potent and selective series of isoxazole based full agonists of S1P1. Isoxazole 6d demonstrated impressive efficacy when administered orally in a rat model of arthritis and in a mouse experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis.

1,3-SUBSTITUTED AZETIDINE PDE10 INHIBITORS

The present invention is directed to substituted azetidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

SECONDARY ALCOHOL SUBSITUTED TRIAZOLES AS PDE10 INHIBITORS

The present invention is directed to secondary alcohol substituted triazole compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

1,3-SUBSTITUTED AZETIDINE PDE10 INHIBITORS

The present invention is directed to substituted azetidinecompounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS

Disclosed are compounds of Formula (I): (I) or stereoisomers, salts, or prodrugs thereof, wherein: (i) R1 and R2 are independently C1-C4 alkyl, or (ii) R1 and R2 together with the carbon atom to which they are a

SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS

Disclosed are compounds of Formula (I), or a stereoisomer or a pharmaceutically acceptable salt thereof, wherein: A is formula (II) Q is a substituted 5-membered monocyclic heteroaryl group; W is CH2, O, or NH; and R1, R2, R3, R4, R5, R6, m, n, t, and x are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

TRICYCLIC HETEROCYCLIC COMPOUNDS

Disclosed are compounds of Formula (I) or stereoisomers or salts thereof, wherein: X1, X2, X3, W, Q1, Q2, and G2 are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

8-METHYL-1-PHENYL-IMIDAZOL[1,5-A]PYRAZINE COMPOUNDS

The present invention provides 8-methyl-1 -phenyl-imidazo[1,5-a]pyrazine derivatives according to formula I or pharmaceutically acceptable salts thereof. The compounds of the current invention show inhibitory activity against Lck and can be used for the treatment of Lck-mediated diseases or Lck-mediated conditions such as inflammatory disorders.